XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues:    
Total revenue $ 2,898,806 $ 2,930,303
Costs and expenses:    
Costs of research and development revenue 1,975,849 2,123,193
Research and development 3,297,266 4,501,365
General and administrative 5,817,013 6,421,505
Foreign currency exchange loss 38,417 49,918
Total costs and expenses 11,128,545 13,095,981
Loss from operations (8,229,739) (10,165,678)
Other income:    
Interest income 416,686 180,420
Gain on sale of Alphazyme 1,017,592 0
Other income 0 250,000
Total other income 1,434,278 430,420
Net loss $ (6,795,461) $ (9,735,258)
Basic and diluted net loss per common share (in dollars per share) $ (0.24) $ (0.34)
Basic and diluted weighted-average common shares outstanding (in shares) 28,798,833 28,364,482
Research and Development [Member]    
Revenues:    
Total revenue $ 2,545,865 $ 2,683,244
License [Member]    
Revenues:    
Total revenue $ 352,941 $ 247,059